vs
Side-by-side financial comparison of Incyte (INCY) and Bio-Techne (TECH). Click either name above to swap in a different company.
Incyte is the larger business by last-quarter revenue ($1.3B vs $295.9M, roughly 4.3× Bio-Techne). Incyte runs the higher net margin — 23.8% vs 12.8%, a 11.0% gap on every dollar of revenue. On growth, Incyte posted the faster year-over-year revenue change (19.8% vs -6.4%). Over the past eight quarters, Incyte's revenue compounded faster (10.4% CAGR vs 4.2%).
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
INCY vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $295.9M |
| Net Profit | $303.3M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 23.7% | 18.4% |
| Net Margin | 23.8% | 12.8% |
| Revenue YoY | 19.8% | -6.4% |
| Net Profit YoY | 91.7% | 68.3% |
| EPS (diluted) | $1.47 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.5B | $295.9M | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.2B | $317.0M | ||
| Q1 25 | $1.1B | $316.2M | ||
| Q4 24 | $1.2B | $297.0M | ||
| Q3 24 | $1.1B | $289.5M | ||
| Q2 24 | $1.0B | $306.1M |
| Q1 26 | $303.3M | — | ||
| Q4 25 | $299.3M | $38.0M | ||
| Q3 25 | $424.2M | — | ||
| Q2 25 | $405.0M | $-17.7M | ||
| Q1 25 | $158.2M | $22.6M | ||
| Q4 24 | $201.2M | $34.9M | ||
| Q3 24 | $106.5M | $33.6M | ||
| Q2 24 | $-444.6M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | 92.0% | 64.6% | ||
| Q3 25 | 92.8% | — | ||
| Q2 25 | 93.5% | 62.7% | ||
| Q1 25 | 93.0% | 67.9% | ||
| Q4 24 | 92.5% | 65.3% | ||
| Q3 24 | 92.4% | 63.2% | ||
| Q2 24 | 92.7% | 66.4% |
| Q1 26 | 23.7% | — | ||
| Q4 25 | 22.3% | 18.4% | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 43.6% | -7.5% | ||
| Q1 25 | 19.5% | 12.2% | ||
| Q4 24 | 25.6% | 16.0% | ||
| Q3 24 | 12.8% | 13.8% | ||
| Q2 24 | -45.8% | 15.0% |
| Q1 26 | 23.8% | — | ||
| Q4 25 | 19.9% | 12.8% | ||
| Q3 25 | 31.1% | — | ||
| Q2 25 | 33.3% | -5.6% | ||
| Q1 25 | 15.0% | 7.1% | ||
| Q4 24 | 17.1% | 11.7% | ||
| Q3 24 | 9.4% | 11.6% | ||
| Q2 24 | -42.6% | 13.3% |
| Q1 26 | $1.47 | — | ||
| Q4 25 | $1.46 | $0.24 | ||
| Q3 25 | $2.11 | — | ||
| Q2 25 | $2.04 | $-0.11 | ||
| Q1 25 | $0.80 | $0.14 | ||
| Q4 24 | $0.90 | $0.22 | ||
| Q3 24 | $0.54 | $0.21 | ||
| Q2 24 | $-2.04 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $5.6B | $2.0B |
| Total Assets | $7.3B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $172.9M | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.0B | $162.2M | ||
| Q1 25 | $1.9B | $140.7M | ||
| Q4 24 | $1.7B | $177.5M | ||
| Q3 24 | $1.3B | $187.5M | ||
| Q2 24 | $987.3M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $5.6B | — | ||
| Q4 25 | $5.2B | $2.0B | ||
| Q3 25 | $4.7B | — | ||
| Q2 25 | $4.2B | $1.9B | ||
| Q1 25 | $3.7B | $2.0B | ||
| Q4 24 | $3.4B | $2.1B | ||
| Q3 24 | $3.2B | $2.1B | ||
| Q2 24 | $3.0B | $2.1B |
| Q1 26 | $7.3B | — | ||
| Q4 25 | $7.0B | $2.5B | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $5.8B | $2.6B | ||
| Q1 25 | $5.7B | $2.6B | ||
| Q4 24 | $5.4B | $2.7B | ||
| Q3 24 | $5.0B | $2.7B | ||
| Q2 24 | $4.7B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INCY
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
